

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

Applicant
Johann Eibl

Filing Date
November 16, 2001

Group
1615

TECH CENTER 1600/2900
JUN 11 2003
RECEIVED



U.S. PATENT DOCUMENTS

*Exam. Init.		Document No.	Date	Name	Class	Subclass	Filing Date ifAppropriate

FOREIGN PATENT DOCUMENT

		Document No.	Date	Country	Class	SubClass	Translator Yes No

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

	1		Fredenburgh et al. Conformational changes in thrombin when complexed by serpins. J Biol Chem. 2001 Nov 30;276(48):44828-34.
	2		Preissner et al. Vitronectin: a new molecular connection in haemostasis. Thromb Haemost. 1991 Aug 1;66(2):189-94.
	3		Kruithof et al. Plasminogen Activator Inhibitor 1:Development of a Radioimmunassay and Observations on its Plasma Concentration During Venous Occlusion and After Platelet Aggregation. Blood. 1987 November 70:1645-1653.
	4		Castellino et al. Enhancement of the streptokinase-induced activation of human plasminogen by human fibrinogen and human fibrinogen fragment D1. Ann N Y Acad Sci. 1983 Jun 27;408:595-601.
	5		Clark et al. Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization. J Invest Dermatol. 1982 Nov;79(5):264-9.
	6		Sakata et al. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest. 1980 Feb;65(2):290-7.
	7		Matras et al. Suture-free interfascicular nerve transplantation in animal experiments. Wien Med Wochenschr. 1972 Sep 9;122(37):517-23.
	8		Thorsen et al. Differences in the binding to fibrin of urokinase and tissue plasminogen activator. Thromb Diath Haemorrh. 1972 Aug 31;28(1):65-74.

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.
A34720-PCT-USA-A
071986.0227

Serial No.
09/998,575

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)**

Applicant
Johann Eibl

Filing Date
November 16, 2001

Group
1615

9

Mosesson et al. The cold-insoluble globulin of human plasma. I. Purification, primary characterization, and relationship to fibrinogen and other cold-insoluble fraction components. J Biol Chem. 1970 Nov 10;245(21):5728-36.



Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Our File No. A34720-PCT-USA-A

0359849227

REC'D #6/B
Dmt
8-1-43

— 1980.01.11 2003.02.26

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Johann Eibl

Serial No. : 09/998,575 Examiner : To Be Assigned
Filed : November 16, 2001 Group Art Unit : 1615
For : MEDICAMENT FOR TOPICAL APPLICATION

AMENDMENT AND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

June 5, 2003

Date of Deposit

Lisa B. Kole

Attorney Name

Signature

35,225

PTO Registration No.

June 5, 2003

Date of Signature

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§1.97 and 1.98, applicant submits herewith copies of the documents listed below in reverse chronological order and on the attached Form PTO-1449. Applicant respectfully requests that the listed documents be considered by the Examiner and made of record in the above-captioned application.

1. Fredenburgh et al. Conformational changes in thrombin when complexed by serpins. *J Biol Chem.* 2001 Nov 30;276(48):44828-34
2. Preissner et al. Vitronectin: a new molecular connection in haemostasis. *Thromb Haemost.* 1991 Aug 1;66(2):189-94.
3. Kruithof et al. Plasminogen Activator Inhibitor 1:Development of a Radioimmunassay and Observations on its Plasma Concentration During Venous Occlusion and After Platelet Aggregation. *Blood.* 1987 November 70:1645-1653.
4. Castellino et al. Enhancement of the streptokinase-induced activation of human plasminogen by human fibrinogen and human fibrinogen fragment D1. *Ann N Y Acad Sci.* 1983 Jun 27;408:595-601.
5. Clark et al. Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization. *J Invest Dermatol.* 1982 Nov;79(5):264-9.
6. Sakata et al. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. *J Clin Invest.* 1980 Feb;65(2):290-7.
7. Matras et al. Suture-free interfascicular nerve transplantation in animal experiments, *Wien Med Wochenschr.* 1972 Sep 9;122(37):517-23.
8. Thorsen et al. Differences in the binding to fibrin of urokinase and tissue plasminogen activator. *Thromb Diath Haemorrh.* 1972 Aug 31;28(1):65-74.
9. Mosesson et al. The cold-insoluble globulin of human plasma. I. Purification, primary characterization, and relationship to fibrinogen and other cold-insoluble fraction components. *J Biol Chem.* 1970 Nov 10;245(21):5728-36.

Applicant has provided a copy of foreign language reference #6. There is currently no readily available English language translation or abstract corresponding to the reference.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute “prior art.” If the Examiner applies the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute “prior art” under United States law, applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of the documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

Applicants respectfully request the Examiner to consider the following amendments to the specification. The two listed changes relate to errors arising from references cited in the specification. The amendment to Mosesson reference corrects an inadvertent error in the page number for the cited reference, i.e. from page 5726 to 5728. The amendment to the plasminogen activator inhibitor reference corrects the author and date of publication of the cited reference. Because the subject matter is similar and the name of the journal and the page numbers for the reference are identical, Applicants believe that Kruithof et al. (Reference #3) is the correct cited reference. As a result, there has been no new matter presented in the amendments proposed below.